Filing Details

Accession Number:
0001104659-21-011783
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-03 20:22:46
Reporting Period:
2021-02-01
Accepted Time:
2021-02-03 20:22:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1633070 Axcella Health Inc. AXLA Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1774648 Manu Chakravarthy C/o Axcella Health Inc.
840 Memorial Drive
Cambridge MA 02139
Svp & Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-01 60,000 $0.00 60,000 No 4 M Direct
Common Stock Disposition 2021-02-01 18,472 $5.50 41,528 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Acquisiton 2021-02-01 60,000 $0.00 60,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
60,000 No 4 M Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one share of AXLA common stock.
  2. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II and does not represent a discretionary trade by the reporting person.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.38 to $5.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. The restricted stock units vested in full on February 1, 2021.